References
- Bannwarth B. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose? Drugs 2012;72:1713–1723.
- Substance Abuse and Mental Health Services Administration. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Rockville, MD: US Department of Health and Human Services; 2015. HHS Publication No. (SMA) 15–4927.
- Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: US Department of Health and Human Services; 2014. HHS Publication No. (SMA) 14–4863.
- Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths - United States, 2000–2014. MMWR Morb Mortal Wkly Rep 2016;64:1378–1382.
- Grady D, Berkowitz SA, Katz MH. Opioids for chronic pain. Arch Intern Med 2011;171:1426–1427.
- Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14:351–358.
- Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011;37:205–217.
- US Food and Drug Administration. Guidance for industry: abuse-deterrent opioids – evaluation and labeling. Silver Spring, MD: US Department of Health and Human Services; 2015.
- Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. J Psychopharmacol 2013;27:808–816.
- Vosburg SK, Jones JD, Manubay JM, et al. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend 2012;126:206–215.
- Vosburg SK, Jones JD, Manubay JM, et al. A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers. Addiction 2013;108:1095–1106.
- Cicero TJ, Ellis MS, Harney J. Abuse prevalence and preference of immediate release versus extended release opioids. RADARS System Technical Report, 2015-Q3; 2015.
- Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Skak N. Crushing and extraction resistance of EG-001, an abuse-deterrent ER morphine in clinical development [abstract 32]. Presented at: PAINWeek, September 2–6, 2014; Las Vegas, NV.
- Smith MD, Webster LR, Lawler J, Lindhardt K, Dayno JM. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (Morphine-ADER Injection-Molded Tablets) versus extended-release morphine administered orally in nondependent recreational opioid users. Pain Med 2016:[Epub ahead of print].
- Webster LR, Smith MD, Lawler J, Lindhardt K, Dayno JM. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (Morphine-ADER Injection-Molded Tablets) vs extended-release morphine administered intranasally in nondependent recreational opioid users. Pain Med 2016:[Epub ahead of print].
- Comer SD, Zacny JP, Dworkin RH, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain 2012;153:2315–2324.
- Turk DC, O’Connor AB, Dworkin RH, et al. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain 2012;153:1997–2008.